New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2012
07:42 EDTAHS, CPHD, CLDX, IART, BIOS, USPH, PBTH, ARNA, DXCM, INSMOppenheimer to host a conference
23rd Annual Healthcare Conference is being held in New York on December 12-13 with webcasted presentations to begin on December 12 at 7:45 am; not all company presentations may be webcasted. Webcast Link
News For AHS;DXCM;ARNA;PBTH;USPH;BIOS;IART;CLDX;CPHD;INSM From The Last 14 Days
Check below for free stories on AHS;DXCM;ARNA;PBTH;USPH;BIOS;IART;CLDX;CPHD;INSM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 26, 2014
10:01 EDTCLDXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:32 EDTARNABioCentury to hold a conference
21st Annual NewsMakers in the Biotech Industry Conference to be held in New York on September 26.
06:35 EDTCLDXCelldex initiated with an Outperform at Cowen
Subscribe for More Information
September 25, 2014
08:07 EDTCLDXCelldex initiates CDX-301 pilot study
Celldex Therapeutics announced the initiation of a pilot study of CDX-301 for the mobilization and transplantation of allogeneic hematopoietic stem cells in patients with hematological malignancies undergoing hematopoietic stem cell transplantation, or HSCT. The study will explore the utility of CDX-301, also known as FMS-like tyrosine kinase-3 ligand or Flt3L, alone and in combination with Mozobil and is supported by preclinical data demonstrating that the combination of CDX-301 and Mozobil increased hematopoietic stem cell mobilization and improved transplantation of mobilized cells. The open-label, pilot study will enroll up to 36 participants, or 18 recipient/donor pairs, ages 18 to 65 across two sequentially enrolled cohorts in approximately 10 clinical trial sites in the United States. Study participants include patients with specified hematologic malignancies and Human Leukocyte Antigen, or HLA, sibling-matched healthy volunteers. The primary objective is to assess the safety and tolerability of CDX-301 when given with or without Mozobil. Secondary endpoints will evaluate the adequacy of the resultant grafts as determined by CD34+ yield, the cellular composition of the resultant grafts, and the safety and effectiveness of the resulting grafts across multiple measures.
September 18, 2014
08:38 EDTIARTIntegra LifeSciences announces commercial release of Integra Freedom system
Subscribe for More Information
07:06 EDTCPHDCepheid weakness creates buying opportunity, says Wells Fargo
Subscribe for More Information
September 17, 2014
11:26 EDTIARTIntegra LifeSciences management to meet with Oppenheimer
Subscribe for More Information
10:00 EDTCPHDOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AB InBev (BUD) upgraded to Hold from Sell at Societe Generale... Baker Hughes (BHI) upgraded to Outperform from Sector Perform at Howard Weil... Bank of the Ozarks (OZRK) upgraded to Buy from Hold at BB&T... Bill Barrett (BBG) upgraded to Buy from Neutral at Mizuho... Cepheid (CPHD) upgraded to Buy from Hold at Cantor... Cigna (CI) upgraded to Positive from Neutral at Susquehanna... Extra Space Storage (EXR) upgraded to Buy from Hold at Jefferies... GNC Holdings (GNC) upgraded to Outperform from Neutral at Wedbush... MB Financial (MBFI) upgraded at DA Davidson... Mondelez (MDLZ) upgraded to Buy from Hold at Societe Generale... Radian Group (RDN) upgraded to Buy from Neutral at Compass Point... Skullcandy (SKUL) assumed with a Overweight from Neutral at Piper Jaffray... Under Armour (UA) upgraded to Overweight from Neutral at Piper Jaffray.
09:23 EDTCPHDCepheid upgraded to Buy from Hold at Cantor
Subscribe for More Information
07:43 EDTARNABofA/Merrill to hold a conference
Subscribe for More Information
07:27 EDTIARTIntegra LifeSciences price target raised to $68 from $59 at Piper Jaffray
Piper Jaffray raised its price target for shares of Integra LifeSciences to $68 saying meetings with the company's CEO increased its confidence in its Overweight rating. Piper thinks Integra's performance will improve in 2015 and expects the stock to significantly outperform over the next 12 months.
06:09 EDTIARTIntegra LifeSciences to acquire Medtronic instrumentation lines for $60M
Integra LifeSciences (IART) and Medtronic (MDT) announced an agreement in which Integra will acquire Medtronic's MicroFrance and Xomed manual ENT and laparoscopy instrumentation lines for approximately $60M in cash. Integra expects the transaction to close in Q4. Integra will acquire a portfolio of approximately 4,000 MicroFrance and Xomed manual ENT and laparoscopic surgical instruments, as well as the St. Aubin le Monial, France manufacturing facility. Sales from the products being acquired totaled approximately $30M, two-thirds of which were generated outside the U.S. Integra expects to record approximately $27M-$30M in revenue and approximately 10c of adjusted EPS in calendar 2015 from this acquisition. The earnings accretion should rise after the first year once certain sales transitions are complete. The company expects the acquisition to contribute less than $5M in revenue and be neutral to earnings in Q4. The transition and integration is expected to be completed by 2H15.
September 16, 2014
09:59 EDTARNAArena to need longer studies of 'Bel-phen' combo to judge safety, TheStreet says
Subscribe for More Information
07:31 EDTDXCMEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use